Literature DB >> 1360508

Receptors involved in the modulation of 5-hydroxytryptamine release in bovine cerebral arteries.

M T Barrús1, J Marín, J Villamor, G Balfagón.   

Abstract

The uptake of [3H]5-hydroxytryptamine (5-HT) in bovine cerebral arteries was reduced by cocaine (1 microM), ouabain (100 microM), pretreatment with 6-hydroxydopamine (6-OHDA) (1.46 mM, 10 min) and metitepine (1 microM). Electrically-stimulated tritium release was decreased by tetrodotoxin (0.8 microM), Ca-free medium, denervation with 6-OHDA (1.46 mM, 10 min), 5-HT (10 microM), noradrenaline (1 microM) and the agonist of alpha 2-adrenoceptors B-HT 920 (0.1 and 1 microM), enhanced by metitepine (1 microM, antagonists of presynaptic 5-HT1 receptors) and rauwolscine (1 microM, antagonist at alpha 2-adrenoceptors, and also of 5-HT1D receptors) and not affected by ketanserin (1 microM, antagonist of 5-HT2 receptors), methysergide (0.1 microM, antagonist of 5-HT1 and 5-HT2 receptors) and phentolamine (1 and 3 microM antagonist of alpha-adrenoceptors and less potent of 5-HT1 receptors). The inhibitory action of 10 microM 5-HT was partially reversed by phentolamine (3 microM) and cocaine (1 microM) and completely reversed by both metitepine (1 microM) and rauwolscine (1 microM). Ketanserin (1 microM), methysergide (0.1 microM) or phentolamine (1 microM) had no effect. Rauwolscine (1 microM) antagonized the inhibition induced by both noradrenaline (1 microM) and B-HT 920 (0.1 and 1 microM). 5-HT induced tritium release which was inhibited by cocaine (an antagonist of 5-HT3 receptors) and denervation with 6-OHDA.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1360508     DOI: 10.1111/j.2042-7158.1992.tb03213.x

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  1 in total

1.  Linkage mapping of alpha-2 adrenergic receptor genes to mouse chromosomes 2 and 5.

Authors:  R E Link; B K Kobilka; G S Barsh
Journal:  Mamm Genome       Date:  1993-11       Impact factor: 2.957

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.